Literature DB >> 30595166

HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients.

Xuelin Feng1, Wenhui Li2, Jie Song1, Xiaoni Liu3, Yuehua Gu3, Chong Yan1, Hui Wu4, Jianying Xi1, Shuizhen Zhou5, Chongbo Zhao6.   

Abstract

To compare HLA typing between juvenile- and adult-onset myasthenia gravis (MG), we enrolled 101 children (age ≤12 years) and 168 adults (age ≥20 years) with MG. We excluded patients with histories of thymoma, thyroid disease, or other autoimmune disease. We selected 41 seronegative juvenile-onset patients with ocular symptoms only, and 41 seropositive adult-onset patients with generalized symptoms. We used next-generation sequencing for typing and analysis of HLA genes (Loci: A, B, C, DPA1, DPB1, DQA1, DQB1 and DRB1). Haplotypes HLA-A∗02:07:01-B∗46:01:01-C∗01:02:01-DQA1∗01:01:01-DQB1∗03:03:02-DRB1∗09:01:02, HLA-A∗11:01:01, HLA-A∗24:02:01, and HLA-DPA1∗02:02:02 were found to be related to juvenile-onset MG and HLA-A∗01:01:01, HLA-A∗02:03:01, HLA-C∗03:04:01, and HLA-DQB1∗06:02:01 to adult-onset MG. Therefore, our findings suggested that HLA typing might determine the heterogeneity between AChR-Ab negative juvenile-onset and AChR-Ab positive adult-onset Chinese MG patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Human leukocyte antigen; Juvenile-onset myasthenia gravis; Myasthenia gravis; Next generation sequencing

Mesh:

Substances:

Year:  2018        PMID: 30595166     DOI: 10.1016/j.jocn.2018.10.077

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  2 in total

Review 1.  Major histocompatibility complex (MHC) associations with diseases in ethnic groups of the Arabian Peninsula.

Authors:  Halima Al Naqbi; Aurélie Mawart; Jawaher Alshamsi; Habiba Al Safar; Guan K Tay
Journal:  Immunogenetics       Date:  2021-02-02       Impact factor: 2.846

Review 2.  Good's Syndrome: Time to Move on From Reviewing the Past.

Authors:  Aunonna Kabir; Reza Alizadehfar; Christos M Tsoukas
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.